Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody‐dependent HER4 intracellular domain trafficking
Human epidermal growth factor receptor 4 (HER4) isoforms have oncogenic or tumor suppressor functions depending on their susceptibility to proteolytic cleavage and HER4 intracellular domain (4ICD) translocation. Here, we report that the neuregulin 1 (NRG1) tumor suppressor mechanism through the HER4...
Saved in:
| Published in: | Cancer science Vol. 111; no. 7; pp. 2508 - 2525 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Tokyo
John Wiley & Sons, Inc
01.07.2020
John Wiley and Sons Inc |
| Subjects: | |
| ISSN: | 1347-9032, 1349-7006, 1349-7006 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Human epidermal growth factor receptor 4 (HER4) isoforms have oncogenic or tumor suppressor functions depending on their susceptibility to proteolytic cleavage and HER4 intracellular domain (4ICD) translocation. Here, we report that the neuregulin 1 (NRG1) tumor suppressor mechanism through the HER4 JMa/CYT1 isoform can be mimicked by the agonist anti‐HER4 Ab C6. Neuregulin 1 induced cleavage of poly(ADP‐ribose) polymerase (PARP) and sub‐G1 DNA fragmentation, and also reduced the metabolic activity of HER3−/HER4+ cervical (C‐33A) and ovarian (COV318) cancer cells. This effect was confirmed in HER4 JMa/CYT1‐, but not JMa/CYT2‐transfected BT549 triple‐negative breast cancer cells. Neuregulin 1 favored 4ICD cleavage and retention in mitochondria in JMa/CYT1‐transfected BT549 cells, leading to reactive oxygen species (ROS) production through mitochondrial depolarization. Similarly, the anti‐HER4 Ab C6, which binds to a conformational epitope located on a.a. 575‐592 and 605‐620 of HER4 domain IV, induced 4ICD cleavage and retention in mitochondria, and mimicked NRG1‐mediated effects on PARP cleavage, ROS production, and mitochondrial membrane depolarization in cancer cells. In vivo, C6 reduced growth of COV434 and HCC1187 tumor cell xenografts in nude mice. Biasing 4ICD trafficking to mitochondria with anti‐HER4 Abs to mimic NRG1 suppressor functions could be an alternative anticancer strategy.
Neuregulin 1 (NRG1) induced cleavage of poly(ADP‐ribose) polymerase (PARP) in human epidermal growth factor receptor 4 (HER4) JMa/CYT1‐expressing cancer cells. NRG1 favored HER4 intracellular domain (4ICD) cleavage and retention into mitochondria leading to reactive oxygen species (ROS) production through mitochondrial depolarization in HER4 JMa/CYT1‐expressing cancer cells. Phage‐displayed selected anti‐HER4 Ab C6 induced 4ICD cleavage and retention into mitochondria, mimicking NRG1‐mediated effects on PARP cleavage, ROS production, and mitochondrial membrane depolarization. C6 Ab reduced in vivo growth of ovarian COV434 and breast HCC1187 tumor cell xenografts in nude mice. |
|---|---|
| AbstractList | Human epidermal growth factor receptor 4 (HER4) isoforms have oncogenic or tumor suppressor functions depending on their susceptibility to proteolytic cleavage and HER4 intracellular domain (4ICD) translocation. Here, we report that the neuregulin 1 (NRG1) tumor suppressor mechanism through the HER4 JMa/CYT1 isoform can be mimicked by the agonist anti‐HER4 Ab C6. Neuregulin 1 induced cleavage of poly(ADP‐ribose) polymerase (PARP) and sub‐G
1
DNA fragmentation, and also reduced the metabolic activity of HER3
−
/HER4
+
cervical (C‐33A) and ovarian (COV318) cancer cells. This effect was confirmed in HER4 JMa/CYT1‐, but not JMa/CYT2‐transfected BT549 triple‐negative breast cancer cells. Neuregulin 1 favored 4ICD cleavage and retention in mitochondria in JMa/CYT1‐transfected BT549 cells, leading to reactive oxygen species (ROS) production through mitochondrial depolarization. Similarly, the anti‐HER4 Ab C6, which binds to a conformational epitope located on a.a. 575‐592 and 605‐620 of HER4 domain IV, induced 4ICD cleavage and retention in mitochondria, and mimicked NRG1‐mediated effects on PARP cleavage, ROS production, and mitochondrial membrane depolarization in cancer cells. In vivo, C6 reduced growth of COV434 and HCC1187 tumor cell xenografts in nude mice. Biasing 4ICD trafficking to mitochondria with anti‐HER4 Abs to mimic NRG1 suppressor functions could be an alternative anticancer strategy. Human epidermal growth factor receptor 4 (HER4) isoforms have oncogenic or tumor suppressor functions depending on their susceptibility to proteolytic cleavage and HER4 intracellular domain (4ICD) translocation. Here, we report that the neuregulin 1 (NRG1) tumor suppressor mechanism through the HER4 JMa/CYT1 isoform can be mimicked by the agonist anti-HER4 Ab C6. Neuregulin 1 induced cleavage of poly(ADP-ribose) polymerase (PARP) and sub-G1 DNA fragmentation, and also reduced the metabolic activity of HER3- /HER4+ cervical (C-33A) and ovarian (COV318) cancer cells. This effect was confirmed in HER4 JMa/CYT1-, but not JMa/CYT2-transfected BT549 triple-negative breast cancer cells. Neuregulin 1 favored 4ICD cleavage and retention in mitochondria in JMa/CYT1-transfected BT549 cells, leading to reactive oxygen species (ROS) production through mitochondrial depolarization. Similarly, the anti-HER4 Ab C6, which binds to a conformational epitope located on a.a. 575-592 and 605-620 of HER4 domain IV, induced 4ICD cleavage and retention in mitochondria, and mimicked NRG1-mediated effects on PARP cleavage, ROS production, and mitochondrial membrane depolarization in cancer cells. In vivo, C6 reduced growth of COV434 and HCC1187 tumor cell xenografts in nude mice. Biasing 4ICD trafficking to mitochondria with anti-HER4 Abs to mimic NRG1 suppressor functions could be an alternative anticancer strategy.Human epidermal growth factor receptor 4 (HER4) isoforms have oncogenic or tumor suppressor functions depending on their susceptibility to proteolytic cleavage and HER4 intracellular domain (4ICD) translocation. Here, we report that the neuregulin 1 (NRG1) tumor suppressor mechanism through the HER4 JMa/CYT1 isoform can be mimicked by the agonist anti-HER4 Ab C6. Neuregulin 1 induced cleavage of poly(ADP-ribose) polymerase (PARP) and sub-G1 DNA fragmentation, and also reduced the metabolic activity of HER3- /HER4+ cervical (C-33A) and ovarian (COV318) cancer cells. This effect was confirmed in HER4 JMa/CYT1-, but not JMa/CYT2-transfected BT549 triple-negative breast cancer cells. Neuregulin 1 favored 4ICD cleavage and retention in mitochondria in JMa/CYT1-transfected BT549 cells, leading to reactive oxygen species (ROS) production through mitochondrial depolarization. Similarly, the anti-HER4 Ab C6, which binds to a conformational epitope located on a.a. 575-592 and 605-620 of HER4 domain IV, induced 4ICD cleavage and retention in mitochondria, and mimicked NRG1-mediated effects on PARP cleavage, ROS production, and mitochondrial membrane depolarization in cancer cells. In vivo, C6 reduced growth of COV434 and HCC1187 tumor cell xenografts in nude mice. Biasing 4ICD trafficking to mitochondria with anti-HER4 Abs to mimic NRG1 suppressor functions could be an alternative anticancer strategy. Human epidermal growth factor receptor 4 (HER4) isoforms have oncogenic or tumor suppressor functions depending on their susceptibility to proteolytic cleavage and HER4 intracellular domain (4ICD) translocation. Here, we report that the neuregulin 1 (NRG1) tumor suppressor mechanism through the HER4 JMa/CYT1 isoform can be mimicked by the agonist anti‐HER4 Ab C6. Neuregulin 1 induced cleavage of poly(ADP‐ribose) polymerase (PARP) and sub‐G1 DNA fragmentation, and also reduced the metabolic activity of HER3−/HER4+ cervical (C‐33A) and ovarian (COV318) cancer cells. This effect was confirmed in HER4 JMa/CYT1‐, but not JMa/CYT2‐transfected BT549 triple‐negative breast cancer cells. Neuregulin 1 favored 4ICD cleavage and retention in mitochondria in JMa/CYT1‐transfected BT549 cells, leading to reactive oxygen species (ROS) production through mitochondrial depolarization. Similarly, the anti‐HER4 Ab C6, which binds to a conformational epitope located on a.a. 575‐592 and 605‐620 of HER4 domain IV, induced 4ICD cleavage and retention in mitochondria, and mimicked NRG1‐mediated effects on PARP cleavage, ROS production, and mitochondrial membrane depolarization in cancer cells. In vivo, C6 reduced growth of COV434 and HCC1187 tumor cell xenografts in nude mice. Biasing 4ICD trafficking to mitochondria with anti‐HER4 Abs to mimic NRG1 suppressor functions could be an alternative anticancer strategy. Neuregulin 1 (NRG1) induced cleavage of poly(ADP‐ribose) polymerase (PARP) in human epidermal growth factor receptor 4 (HER4) JMa/CYT1‐expressing cancer cells. NRG1 favored HER4 intracellular domain (4ICD) cleavage and retention into mitochondria leading to reactive oxygen species (ROS) production through mitochondrial depolarization in HER4 JMa/CYT1‐expressing cancer cells. Phage‐displayed selected anti‐HER4 Ab C6 induced 4ICD cleavage and retention into mitochondria, mimicking NRG1‐mediated effects on PARP cleavage, ROS production, and mitochondrial membrane depolarization. C6 Ab reduced in vivo growth of ovarian COV434 and breast HCC1187 tumor cell xenografts in nude mice. Human epidermal growth factor receptor 4 (HER4) isoforms have oncogenic or tumor suppressor functions depending on their susceptibility to proteolytic cleavage and HER4 intracellular domain (4ICD) translocation. Here, we report that the neuregulin 1 (NRG1) tumor suppressor mechanism through the HER4 JMa/CYT1 isoform can be mimicked by the agonist anti‐HER4 Ab C6. Neuregulin 1 induced cleavage of poly(ADP‐ribose) polymerase (PARP) and sub‐G1 DNA fragmentation, and also reduced the metabolic activity of HER3−/HER4+ cervical (C‐33A) and ovarian (COV318) cancer cells. This effect was confirmed in HER4 JMa/CYT1‐, but not JMa/CYT2‐transfected BT549 triple‐negative breast cancer cells. Neuregulin 1 favored 4ICD cleavage and retention in mitochondria in JMa/CYT1‐transfected BT549 cells, leading to reactive oxygen species (ROS) production through mitochondrial depolarization. Similarly, the anti‐HER4 Ab C6, which binds to a conformational epitope located on a.a. 575‐592 and 605‐620 of HER4 domain IV, induced 4ICD cleavage and retention in mitochondria, and mimicked NRG1‐mediated effects on PARP cleavage, ROS production, and mitochondrial membrane depolarization in cancer cells. In vivo, C6 reduced growth of COV434 and HCC1187 tumor cell xenografts in nude mice. Biasing 4ICD trafficking to mitochondria with anti‐HER4 Abs to mimic NRG1 suppressor functions could be an alternative anticancer strategy. Human epidermal growth factor receptor 4 (HER4) isoforms have oncogenic or tumor suppressor functions depending on their susceptibility to proteolytic cleavage and HER4 intracellular domain (4ICD) translocation. Here, we report that the neuregulin 1 (NRG1) tumor suppressor mechanism through the HER4 JMa/CYT1 isoform can be mimicked by the agonist anti‐HER4 Ab C6. Neuregulin 1 induced cleavage of poly(ADP‐ribose) polymerase (PARP) and sub‐G1 DNA fragmentation, and also reduced the metabolic activity of HER3−/HER4+ cervical (C‐33A) and ovarian (COV318) cancer cells. This effect was confirmed in HER4 JMa/CYT1‐, but not JMa/CYT2‐transfected BT549 triple‐negative breast cancer cells. Neuregulin 1 favored 4ICD cleavage and retention in mitochondria in JMa/CYT1‐transfected BT549 cells, leading to reactive oxygen species (ROS) production through mitochondrial depolarization. Similarly, the anti‐HER4 Ab C6, which binds to a conformational epitope located on a.a. 575‐592 and 605‐620 of HER4 domain IV, induced 4ICD cleavage and retention in mitochondria, and mimicked NRG1‐mediated effects on PARP cleavage, ROS production, and mitochondrial membrane depolarization in cancer cells. In vivo, C6 reduced growth of COV434 and HCC1187 tumor cell xenografts in nude mice. Biasing 4ICD trafficking to mitochondria with anti‐HER4 Abs to mimic NRG1 suppressor functions could be an alternative anticancer strategy. Neuregulin 1 (NRG1) induced cleavage of poly(ADP‐ribose) polymerase (PARP) in human epidermal growth factor receptor 4 (HER4) JMa/CYT1‐expressing cancer cells. NRG1 favored HER4 intracellular domain (4ICD) cleavage and retention into mitochondria leading to reactive oxygen species (ROS) production through mitochondrial depolarization in HER4 JMa/CYT1‐expressing cancer cells. Phage‐displayed selected anti‐HER4 Ab C6 induced 4ICD cleavage and retention into mitochondria, mimicking NRG1‐mediated effects on PARP cleavage, ROS production, and mitochondrial membrane depolarization. C6 Ab reduced in vivo growth of ovarian COV434 and breast HCC1187 tumor cell xenografts in nude mice. |
| Author | Martineau, Pierre Pèlegrin, André Gaborit, Nadège Chardès, Thierry Garambois, Véronique Lanotte, Romain Larbouret, Christel Musnier, Astrid |
| AuthorAffiliation | 3 Centre National de la Recherche Scientifique (CNRS) Paris France 4 Present address: CNRS UMR 9002 Institut de Génétique Humaine Montpellier France 2 MAbSilico SAS Centre de Recherche INRA Val de Loire Nouzilly France 1 Institut de Recherche en Cancérologie de Montpellier (IRCM) INSERM U1194 Université de Montpellier, Institut régional du Cancer de Montpellier (ICM) Montpellier France |
| AuthorAffiliation_xml | – name: 3 Centre National de la Recherche Scientifique (CNRS) Paris France – name: 4 Present address: CNRS UMR 9002 Institut de Génétique Humaine Montpellier France – name: 2 MAbSilico SAS Centre de Recherche INRA Val de Loire Nouzilly France – name: 1 Institut de Recherche en Cancérologie de Montpellier (IRCM) INSERM U1194 Université de Montpellier, Institut régional du Cancer de Montpellier (ICM) Montpellier France |
| Author_xml | – sequence: 1 givenname: Romain surname: Lanotte fullname: Lanotte, Romain organization: Université de Montpellier, Institut régional du Cancer de Montpellier (ICM) – sequence: 2 givenname: Véronique surname: Garambois fullname: Garambois, Véronique organization: Université de Montpellier, Institut régional du Cancer de Montpellier (ICM) – sequence: 3 givenname: Nadège surname: Gaborit fullname: Gaborit, Nadège organization: Université de Montpellier, Institut régional du Cancer de Montpellier (ICM) – sequence: 4 givenname: Christel surname: Larbouret fullname: Larbouret, Christel organization: Université de Montpellier, Institut régional du Cancer de Montpellier (ICM) – sequence: 5 givenname: Astrid surname: Musnier fullname: Musnier, Astrid organization: Centre de Recherche INRA Val de Loire – sequence: 6 givenname: Pierre surname: Martineau fullname: Martineau, Pierre organization: Université de Montpellier, Institut régional du Cancer de Montpellier (ICM) – sequence: 7 givenname: André surname: Pèlegrin fullname: Pèlegrin, André organization: Université de Montpellier, Institut régional du Cancer de Montpellier (ICM) – sequence: 8 givenname: Thierry orcidid: 0000-0002-1836-7439 surname: Chardès fullname: Chardès, Thierry email: thierry.chardes@inserm.fr organization: Centre National de la Recherche Scientifique (CNRS) |
| BookMark | eNp9ks1u1DAQxy1URNuFA29giUt7SOvEzhcHpLIqtFIlJD7Olj_GWZfEXuyEVW48Ao_D8_AkON2CRCWwZXlk__4z4_EcowPnHSD0PCdneRrnSsSznLGyeYSOcsrarCakOriz66wltDhExzHeEkIr1rIn6JAWLC-bqjlCP15bEa3r8GYahMOwtRrCIHrcBb8bN9gINfqAAyjYLgbDJ1eX79kpHufgkxDwZ-tEBBxt50S_eNrZpBNutNJrC_ElvnZ6UqP1DnuDFfQ91iASI-ff2Pzz23cNW3Aa3IiXANi6MYgFnnoRsPaDsA6nI2OsSiG7p-ixEX2EZ_f7Cn16c_lxfZXdvHt7vb64yRRjrMmooTpVgYi6aaiWhlFQui1LyYxgQGpS50pJmWujC1lQ2VLQdUU0M7WWrTR0hV7t_W4nOYBWsOTV822wgwgz98Lyv2-c3fDOf-U1bUqagq7Qyb2D4L9MEEc-2Lg8TDjwU-QFI2k2tMgT-uIBeuunkMq6UEXNyrSqRJ3uKZV-IAYwf5LJCV_6gad-4Hf9kNjzB6yyo1j-IuVq-_8pdraH-d-u-friw17xC13QzR0 |
| CitedBy_id | crossref_primary_10_3390_biology14091225 crossref_primary_10_3390_ijms25137475 crossref_primary_10_1016_j_cellsig_2022_110401 |
| Cites_doi | 10.2353/ajpath.2009.090204 10.1016/j.bbrc.2016.01.045 10.1038/sj.onc.1210501 10.1128/MCB.01705-08 10.1111/bph.12416 10.1371/journal.pone.0039413 10.1002/ijc.21818 10.1074/jbc.271.13.7620 10.1073/pnas.1201114109 10.1091/mbc.e05-05-0402 10.1186/1471-2407-13-437 10.1038/ncb2738 10.1016/j.molmed.2017.03.004 10.1038/nrc2694 10.1016/j.phrs.2013.11.002 10.1038/nrd4052 10.1016/j.bcp.2012.08.021 10.1016/j.bbabio.2006.04.029 10.1074/jbc.275.12.8641 10.1126/science.1065412 10.1126/science.287.5453.664 10.1186/s12885-016-2195-3 10.18632/oncotarget.12485 10.1158/0008-5472.CAN-06-4145 10.1126/scisignal.2005770 10.1007/s10911-008-9076-6 10.1038/onc.2008.481 10.1002/jso.20892 10.1128/MCB.01950-05 10.1002/pros.20555 10.1016/j.bbrc.2006.08.055 10.1016/j.bbrep.2016.07.015 10.1091/mbc.E06-02-0101 10.1016/j.jmb.2014.08.013 10.2217/fon.09.144 10.1073/pnas.1313671110 10.1073/pnas.0708333105 10.1158/1541-7786.MCR-13-0637 10.1152/physrev.00011.2017 10.1158/1541-7786.MCR-10-0042 10.1038/onc.2009.259 10.1038/cddis.2017.42 10.1038/onc.2010.271 10.4161/cc.10.16.17194 10.1158/0008-5472.CAN-05-2368 10.1593/neo.121960 10.1016/j.bbabio.2006.06.014 10.1186/s13058-014-0501-z 10.1158/1078-0432.CCR-15-0306 10.1002/ijc.11273 10.1016/j.ygyno.2012.12.044 |
| ContentType | Journal Article |
| Copyright | 2020 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. 2020. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. |
| Copyright_xml | – notice: 2020 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. – notice: 2020. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. |
| DBID | 24P AAYXX CITATION 3V. 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1111/cas.14458 |
| DatabaseName | Wiley Online Library Open Access CrossRef ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection PML(ProQuest Medical Library) Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | LANOTTE et al |
| EISSN | 1349-7006 |
| EndPage | 2525 |
| ExternalDocumentID | PMC7385388 10_1111_cas_14458 CAS14458 |
| Genre | article |
| GrantInformation_xml | – fundername: LabEx MAbImprove funderid: ANR‐10‐LABX‐53‐01 – fundername: INSERM Transfert funderid: CoPoc HER4Valid – fundername: LabEx MAbImprove grantid: ANR‐10‐LABX‐53‐01 – fundername: INSERM Transfert grantid: CoPoc HER4Valid |
| GroupedDBID | --- .3N .55 .GA .Y3 05W 0R~ 10A 1OC 24P 29B 2WC 31~ 36B 3O- 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52W 52X 53G 5GY 5HH 5LA 5VS 66C 7.U 702 7PT 8-0 8-1 8-3 8-4 8-5 8FE 8FH 8UM 930 A01 A03 AAHHS AAZKR ABCQN ABEML ACCFJ ACCMX ACSCC ACXQS ADBBV ADKYN ADPDF ADZMN ADZOD AEEZP AENEX AEQDE AFBPY AFEBI AFFNX AFKRA AFPKN AFZJQ AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AOIJS AVUZU BAWUL BBNVY BCNDV BENPR BFHJK BHPHI BY8 CAG CCPQU COF CS3 D-6 D-7 D-E D-F DIK DR2 DU5 E3Z EBS EJD EMB EMOBN EX3 F00 F01 F04 F5P FIJ GODZA GROUPED_DOAJ HCIFZ HF~ HOLLA HYE HZI HZ~ IAO IHR IPNFZ ITC IX1 J0M K.9 K48 KQ8 LC2 LC3 LH4 LK8 LP6 LP7 LW6 M7P MK4 N04 N05 N9A O9- OIG OK1 OVD P2P P2X P2Z P4B P4D PIMPY PROAC Q11 ROL RPM RX1 SJN SUPJJ SV3 TEORI UB1 W8V WIN WOW WQJ WRC WXI X7M XG1 ZXP ~IA ~WT 7X7 88E 8FI 8FJ AAFWJ AAMMB AAYXX ABUWG AEFGJ AFFHD AGXDD AIDQK AIDYY CITATION FYUFA HMCUK M1P O8X PHGZM PHGZT PJZUB PPXIY PQGLB PSQYO UKHRP 3V. 7XB 8FK AZQEC DWQXO GNUQQ K9. PKEHL PQEST PQQKQ PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c4448-3f3d3470a7883dbf43ecd955b4fa4e07071ccbb1dfd2b23b93ed760d4f7db9bf3 |
| IEDL.DBID | M7P |
| ISICitedReferencesCount | 3 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000538607600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1347-9032 1349-7006 |
| IngestDate | Tue Nov 04 01:48:05 EST 2025 Thu Sep 04 20:11:05 EDT 2025 Tue Oct 07 07:26:10 EDT 2025 Sat Nov 29 02:47:00 EST 2025 Tue Nov 18 22:20:27 EST 2025 Wed Jan 22 16:34:37 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Language | English |
| License | Attribution-NonCommercial This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4448-3f3d3470a7883dbf43ecd955b4fa4e07071ccbb1dfd2b23b93ed760d4f7db9bf3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-1836-7439 |
| OpenAccessLink | https://www.proquest.com/docview/2427452746?pq-origsite=%requestingapplication% |
| PMID | 32415868 |
| PQID | 2427452746 |
| PQPubID | 4378882 |
| PageCount | 18 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7385388 proquest_miscellaneous_2404048321 proquest_journals_2427452746 crossref_primary_10_1111_cas_14458 crossref_citationtrail_10_1111_cas_14458 wiley_primary_10_1111_cas_14458_CAS14458 |
| PublicationCentury | 2000 |
| PublicationDate | July 2020 |
| PublicationDateYYYYMMDD | 2020-07-01 |
| PublicationDate_xml | – month: 07 year: 2020 text: July 2020 |
| PublicationDecade | 2020 |
| PublicationPlace | Tokyo |
| PublicationPlace_xml | – name: Tokyo – name: Hoboken |
| PublicationTitle | Cancer science |
| PublicationYear | 2020 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc |
| References | 2017; 8 2006; 119 2006; 17 2013; 129 2013; 85 2017; 23 2011; 10 2008; 13 2008; 105 2000; 275 2008; 97 2009; 175 2014; 171 2016; 16 2009; 29 2012; 109 2009; 28 2014; 426 2016; 7 2013; 15 2001; 294 2003; 106 2010; 29 2013; 13 2006; 66 2013; 12 2006; 1757 2006; 26 2014; 16 1950; 2018 1996; 271 2009; 9 2014; 79 2013; 110 2000; 287 2012; 7 2014; 7 2006; 349 2018; 98 2007; 67 2014; 12 2010; 6 2007; 26 2016; 470 2016; 22 2010; 8 e_1_2_8_28_1 e_1_2_8_24_1 e_1_2_8_47_1 e_1_2_8_26_1 e_1_2_8_49_1 e_1_2_8_3_1 e_1_2_8_5_1 e_1_2_8_7_1 e_1_2_8_9_1 e_1_2_8_20_1 e_1_2_8_43_1 e_1_2_8_22_1 e_1_2_8_45_1 e_1_2_8_41_1 e_1_2_8_17_1 e_1_2_8_19_1 e_1_2_8_13_1 e_1_2_8_36_1 e_1_2_8_15_1 e_1_2_8_38_1 e_1_2_8_11_1 e_1_2_8_34_1 e_1_2_8_53_1 e_1_2_8_51_1 e_1_2_8_30_1 e_1_2_8_29_1 e_1_2_8_25_1 e_1_2_8_46_1 e_1_2_8_27_1 e_1_2_8_48_1 e_1_2_8_2_1 e_1_2_8_4_1 e_1_2_8_6_1 e_1_2_8_8_1 e_1_2_8_21_1 e_1_2_8_42_1 e_1_2_8_23_1 e_1_2_8_44_1 e_1_2_8_40_1 e_1_2_8_18_1 e_1_2_8_39_1 e_1_2_8_14_1 e_1_2_8_35_1 e_1_2_8_16_1 e_1_2_8_37_1 Bourquard T (e_1_2_8_32_1) 1950; 2018 e_1_2_8_10_1 e_1_2_8_31_1 e_1_2_8_12_1 e_1_2_8_33_1 e_1_2_8_52_1 e_1_2_8_50_1 |
| References_xml | – volume: 29 start-page: 4935 year: 2009 end-page: 4948 article-title: ErbB4 splice variants Cyt1 and Cyt2 differ by 16 amino acids and exert opposing effects on the mammary epithelium in vivo publication-title: Mol Cell Biol – volume: 349 start-page: 372 year: 2006 end-page: 382 article-title: Phosphorylation of ErbB4 on Tyr1056 is critical for inhibition of colony formation by prostate tumor cell lines publication-title: Biochem Biophys Res Commun – volume: 10 start-page: 2647 year: 2011 end-page: 2657 article-title: Function of ERBB4 is determined by alternative splicing publication-title: Cell Cycle Georget Tex – volume: 16 start-page: 138 year: 2016 article-title: Prognostic value of ERBB4 expression in patients with triple negative breast cancer publication-title: BMC Cancer – volume: 12 start-page: 630 year: 2013 end-page: 644 article-title: Emerging paradigms in GPCR allostery: implications for drug discovery publication-title: Nat Rev Drug Discov – volume: 28 start-page: 1309 year: 2009 end-page: 1319 article-title: Suppression of breast cancer cell growth by a monoclonal antibody targeting cleavable ErbB4 isoforms publication-title: Oncogene – volume: 7 start-page: 76693 year: 2016 end-page: 76703 article-title: Human epidermal growth factor receptor 4 (HER4) is a favorable prognostic marker of breast cancer: a systematic review and meta‐analysis publication-title: Oncotarget – volume: 13 start-page: 437 year: 2013 article-title: The prognostic value of Her4 receptor isoform expression in triple‐negative and Her2 positive breast cancer patients publication-title: BMC Cancer – volume: 7 start-page: 323 year: 2016 end-page: 327 article-title: Direct coupling of the HER4 intracellular domain (4ICD) and STAT5A signaling is required to induce mammary epithelial cell differentiation publication-title: Biochem Biophys Rep – volume: 85 start-page: 147 year: 2013 end-page: 152 article-title: Opportunities for functional selectivity in GPCR antibodies publication-title: Biochem Pharmacol – volume: 105 start-page: 4162 year: 2008 end-page: 4167 article-title: Isoform‐specific monoubiquitination, endocytosis, and degradation of alternatively spliced ErbB4 isoforms publication-title: Proc Natl Acad Sci USA – volume: 8 start-page: 1388 year: 2010 end-page: 1398 article-title: Interactions of ErbB4 and Kap1 connect the growth factor and DNA damage response pathways publication-title: Mol Cancer Res – volume: 29 start-page: 5214 year: 2010 end-page: 5219 article-title: Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells publication-title: Oncogene – volume: 97 start-page: 44 year: 2008 end-page: 50 article-title: Nuclear translocation of HER‐4/c‐erbB‐4 is significantly correlated with prognosis of esophageal squamous cell carcinoma publication-title: J Surg Oncol – volume: 23 start-page: 411 year: 2017 end-page: 429 article-title: ROS in cancer: the burning question publication-title: Trends Mol Med – volume: 8 year: 2017 article-title: ErbB4 signaling stimulates pro‐inflammatory macrophage apoptosis and limits colonic inflammation publication-title: Cell Death Dis – volume: 275 start-page: 8641 year: 2000 end-page: 8649 article-title: A natural ErbB4 isoform that does not activate phosphoinositide 3‐kinase mediates proliferation but not survival or chemotaxis publication-title: J Biol Chem – volume: 26 start-page: 6905 year: 2007 end-page: 6914 article-title: Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains publication-title: Oncogene – volume: 15 start-page: 335 year: 2013 end-page: 347 article-title: Anti‐HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT‐induced MDM2, XIAP, and FoxO1 phosphorylation publication-title: Neoplasia – volume: 9 start-page: 537 year: 2009 end-page: 549 article-title: Signal integration by JNK and p38 MAPK pathways in cancer development publication-title: Nat Rev Cancer – volume: 22 start-page: 1284 year: 2016 end-page: 1294 article-title: Elevated coexpression of KITENIN and the ErbB4 CYT‐2 isoform promotes the transition from colon adenoma to carcinoma following APC loss publication-title: Clin Cancer Res – volume: 175 start-page: 1802 year: 2009 end-page: 1809 article-title: Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients publication-title: Am J Pathol – volume: 67 start-page: 6582 year: 2007 end-page: 6590 article-title: HER4 D‐box sequences regulate mitotic progression and degradation of the nuclear HER4 cleavage product s80HER4 publication-title: Cancer Res – volume: 26 start-page: 6412 year: 2006 end-page: 6424 article-title: Heregulin‐dependent delay in mitotic progression requires HER4 and BRCA1 publication-title: Mol Cell Biol – volume: 1757 start-page: 509 year: 2006 end-page: 517 article-title: Mitochondrial ROS‐induced ROS release: an update and review publication-title: Biochim Biophys Acta – volume: 119 start-page: 269 year: 2006 end-page: 274 article-title: ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti‐cancer therapy publication-title: Int J Cancer – volume: 12 start-page: 1140 year: 2014 end-page: 1155 article-title: Convergent and divergent cellular responses by ErbB4 isoforms in mammary epithelial cells publication-title: Mol Cancer Res – volume: 28 start-page: 4041 year: 2009 end-page: 4052 article-title: The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene publication-title: Oncogene – volume: 66 start-page: 6412 year: 2006 end-page: 6420 article-title: The ERBB4/HER4 intracellular domain 4ICD is a BH3‐only protein promoting apoptosis of breast cancer cells publication-title: Cancer Res – volume: 171 start-page: 2000 year: 2014 end-page: 2016 article-title: Parthanatos: mitochondrial‐linked mechanisms and therapeutic opportunities publication-title: Br J Pharmacol – volume: 109 start-page: 10861 year: 2012 end-page: 10866 article-title: A single ligand is sufficient to activate EGFR dimers publication-title: Proc Natl Acad Sci USA – volume: 6 start-page: 37 year: 2010 end-page: 53 article-title: Potential of ErbB4 antibodies for cancer therapy publication-title: Future Oncol – volume: 106 start-page: 758 year: 2003 end-page: 765 article-title: Prognostic value of ERBB family mRNA expression in breast carcinomas publication-title: Int J Cancer – volume: 13 start-page: 247 year: 2008 end-page: 258 article-title: HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer publication-title: J Mammary Gland Biol Neoplasia – volume: 79 start-page: 34 year: 2014 end-page: 74 article-title: The ErbB/HER family of protein‐tyrosine kinases and cancer publication-title: Pharmacol Res – volume: 426 start-page: 3729 year: 2014 end-page: 3743 article-title: Restricted diversity of antigen binding residues of antibodies revealed by computational alanine scanning of 227 antibody‐antigen complexes publication-title: J Mol Biol – volume: 470 start-page: 239 year: 2016 end-page: 244 article-title: Development of an ErbB4 monoclonal antibody that blocks neuregulin‐1‐induced ErbB4 activation in cancer cells publication-title: Biochem Biophys Res Commun – volume: 2018 start-page: 3096 issue: 201 year: 1950 end-page: 3105 article-title: MAbTope: a method for improved epitope mapping publication-title: J Immunol – volume: 1757 start-page: 1371 year: 2006 end-page: 1387 article-title: Necrosis, a well‐orchestrated form of cell demise: signalling cascades, important mediators and concomitant immune response publication-title: Biochim Biophys Acta – volume: 17 start-page: 67 year: 2006 end-page: 79 article-title: Proteolytic cleavage and phosphorylation of a tumor‐associated ErbB4 isoform promote ligand‐independent survival and cancer cell growth publication-title: Mol Biol Cell – volume: 271 start-page: 7620 year: 1996 end-page: 7629 article-title: An immunological approach reveals biological differences between the two NDF/heregulin receptors, ErbB‐3 and ErbB‐4 publication-title: J Biol Chem – volume: 67 start-page: 871 year: 2007 end-page: 880 article-title: ErbB‐4 may control behavior of prostate cancer cells and serve as a target for molecular therapy publication-title: Prostate – volume: 294 start-page: 2179 year: 2001 end-page: 2181 article-title: gamma ‐Secretase cleavage and nuclear localization of ErbB‐4 receptor tyrosine kinase publication-title: Science – volume: 15 start-page: 481 year: 2013 end-page: 490 article-title: ER‐stress‐induced transcriptional regulation increases protein synthesis leading to cell death publication-title: Nat Cell Biol – volume: 7 start-page: ra116 year: 2014 article-title: Neuregulin 1‐activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration publication-title: Sci Signal – volume: 16 start-page: 501 year: 2014 article-title: Overexpression of ERBB4 JM‐a CYT‐1 and CYT‐2 isoforms in transgenic mice reveals isoform‐specific roles in mammary gland development and carcinogenesis publication-title: Breast Cancer Res – volume: 110 start-page: 14966 year: 2013 end-page: 14971 article-title: Converting stem cells to dendritic cells by agonist antibodies from unbiased morphogenic selections publication-title: Proc Natl Acad Sci USA – volume: 17 start-page: 4118 year: 2006 end-page: 4129 article-title: The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells publication-title: Mol Biol Cell – volume: 129 start-page: 179 year: 2013 end-page: 187 article-title: CYT‐1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro publication-title: Gynecol Oncol – volume: 98 start-page: 813 year: 2018 end-page: 880 article-title: Neuronal cell death publication-title: Physiol Rev – volume: 7 year: 2012 article-title: Proteolytic processing of ErbB4 in breast cancer publication-title: PLoS One – volume: 287 start-page: 664 year: 2000 end-page: 666 article-title: Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1 publication-title: Science – ident: e_1_2_8_21_1 doi: 10.2353/ajpath.2009.090204 – ident: e_1_2_8_44_1 doi: 10.1016/j.bbrc.2016.01.045 – ident: e_1_2_8_15_1 doi: 10.1038/sj.onc.1210501 – ident: e_1_2_8_19_1 doi: 10.1128/MCB.01705-08 – ident: e_1_2_8_48_1 doi: 10.1111/bph.12416 – ident: e_1_2_8_53_1 doi: 10.1371/journal.pone.0039413 – ident: e_1_2_8_40_1 doi: 10.1002/ijc.21818 – ident: e_1_2_8_38_1 doi: 10.1074/jbc.271.13.7620 – ident: e_1_2_8_50_1 doi: 10.1073/pnas.1201114109 – ident: e_1_2_8_17_1 doi: 10.1091/mbc.e05-05-0402 – ident: e_1_2_8_42_1 doi: 10.1186/1471-2407-13-437 – ident: e_1_2_8_46_1 doi: 10.1038/ncb2738 – ident: e_1_2_8_37_1 doi: 10.1016/j.molmed.2017.03.004 – ident: e_1_2_8_33_1 doi: 10.1038/nrc2694 – ident: e_1_2_8_2_1 doi: 10.1016/j.phrs.2013.11.002 – volume: 2018 start-page: 3096 issue: 201 year: 1950 ident: e_1_2_8_32_1 article-title: MAbTope: a method for improved epitope mapping publication-title: J Immunol – ident: e_1_2_8_52_1 doi: 10.1038/nrd4052 – ident: e_1_2_8_29_1 doi: 10.1016/j.bcp.2012.08.021 – ident: e_1_2_8_49_1 doi: 10.1016/j.bbabio.2006.04.029 – ident: e_1_2_8_11_1 doi: 10.1074/jbc.275.12.8641 – ident: e_1_2_8_8_1 doi: 10.1126/science.1065412 – ident: e_1_2_8_47_1 doi: 10.1126/science.287.5453.664 – ident: e_1_2_8_5_1 doi: 10.1186/s12885-016-2195-3 – ident: e_1_2_8_6_1 doi: 10.18632/oncotarget.12485 – ident: e_1_2_8_26_1 doi: 10.1158/0008-5472.CAN-06-4145 – ident: e_1_2_8_9_1 doi: 10.1126/scisignal.2005770 – ident: e_1_2_8_23_1 doi: 10.1007/s10911-008-9076-6 – ident: e_1_2_8_43_1 doi: 10.1038/onc.2008.481 – ident: e_1_2_8_12_1 doi: 10.1002/jso.20892 – ident: e_1_2_8_34_1 doi: 10.1128/MCB.01950-05 – ident: e_1_2_8_51_1 doi: 10.1002/pros.20555 – ident: e_1_2_8_28_1 doi: 10.1016/j.bbrc.2006.08.055 – ident: e_1_2_8_39_1 doi: 10.1016/j.bbrep.2016.07.015 – ident: e_1_2_8_25_1 doi: 10.1091/mbc.E06-02-0101 – ident: e_1_2_8_31_1 doi: 10.1016/j.jmb.2014.08.013 – ident: e_1_2_8_4_1 doi: 10.2217/fon.09.144 – ident: e_1_2_8_30_1 doi: 10.1073/pnas.1313671110 – ident: e_1_2_8_14_1 doi: 10.1073/pnas.0708333105 – ident: e_1_2_8_18_1 doi: 10.1158/1541-7786.MCR-13-0637 – ident: e_1_2_8_45_1 doi: 10.1152/physrev.00011.2017 – ident: e_1_2_8_35_1 doi: 10.1158/1541-7786.MCR-10-0042 – ident: e_1_2_8_27_1 doi: 10.1038/onc.2009.259 – ident: e_1_2_8_22_1 doi: 10.1038/cddis.2017.42 – ident: e_1_2_8_24_1 doi: 10.1038/onc.2010.271 – ident: e_1_2_8_7_1 doi: 10.4161/cc.10.16.17194 – ident: e_1_2_8_20_1 doi: 10.1158/0008-5472.CAN-05-2368 – ident: e_1_2_8_3_1 doi: 10.1593/neo.121960 – ident: e_1_2_8_36_1 doi: 10.1016/j.bbabio.2006.06.014 – ident: e_1_2_8_10_1 doi: 10.1186/s13058-014-0501-z – ident: e_1_2_8_16_1 doi: 10.1158/1078-0432.CCR-15-0306 – ident: e_1_2_8_41_1 doi: 10.1002/ijc.11273 – ident: e_1_2_8_13_1 doi: 10.1016/j.ygyno.2012.12.044 |
| SSID | ssj0036494 |
| Score | 2.321595 |
| Snippet | Human epidermal growth factor receptor 4 (HER4) isoforms have oncogenic or tumor suppressor functions depending on their susceptibility to proteolytic cleavage... |
| SourceID | pubmedcentral proquest crossref wiley |
| SourceType | Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 2508 |
| SubjectTerms | 4ICD antibody Apoptosis Breast cancer cancer Cell cycle Cell death Cell growth Cervix Depolarization DNA fragmentation Epidermal growth factor Epitopes Experiments Flow cytometry HER4 Intracellular Intracellular signalling Isoforms Kinases Ligands Medical prognosis Membrane potential Mitochondria Neuregulin Neuregulin 1 Original Ovarian cancer Poly(ADP-ribose) polymerase Protein-tyrosine kinase Proteolysis Reactive oxygen species Ribose Tumor suppressor genes Xenografts |
| SummonAdditionalLinks | – databaseName: Wiley Online Library Open Access dbid: 24P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZKQagX3oiFFg2Iw3KIFMfOJoZTqVr1AFXFS71Fdmy3ESWpummlvfUn9Ofwe_glzDiPdhFISBwiRckkTjIPz0zG8zH2Ci1erlOlo9wlLpKa28hw4yI6ZhJlfR6q3b--z_b28oMDtb_C3g5rYbr-EGPCjTQj2GtScG3m15ScIMEwGkjzG-wm5yIjkU7k_mCGxUyqDtFWZpGKRdK3FaIynvHS5cnoysP8vT7yut8aJp6du__1yPfYnd7fhM1OQO6zFVc_YLc_9H_UH7If7ypN6QIIYH3gCDAWbfUxHGJ83h5Bh8cDaBfdCe1ImO5uf5SvoV3gK-Et4FtV40wIVAiiaW07UGoXkGGVaahE8Q0QPEhYPgGNB_pTAJYcTzCLgWzx8-JygONtgQaAij4KEVOdLNjmu65qwEPU8oLS-4_Yl53tz1u7UY_mEJUSY8BIeGGRF7HGoFtY46VwpVVpaqTX0lHXIV6WxnDrbWISYZRwNpvFVvrMGmW8eMxW66Z2TxjEWZJw6zD40qV0pTReKRN7NUstBpCcT9h0YGtR9q3OCXHjuBhCHuREETgxYS9H0pOuv8efiNYH2Sh6FZ8X6NtkMsVtNmEvxtOonPRpdO2aM6JBGykJDGrCsiWZGgej9t7LZ-rqKLT5pj5DIsfBp0Gm_v54xdbmp7Dz9N9Jn7G1hDIHofB4na22p2dug90qz9tqfvo8aNIvcVIn3Q priority: 102 providerName: Wiley-Blackwell |
| Title | Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody‐dependent HER4 intracellular domain trafficking |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcas.14458 https://www.proquest.com/docview/2427452746 https://www.proquest.com/docview/2404048321 https://pubmed.ncbi.nlm.nih.gov/PMC7385388 |
| Volume | 111 |
| WOSCitedRecordID | wos000538607600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1349-7006 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0036494 issn: 1347-9032 databaseCode: DOA dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1349-7006 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0036494 issn: 1347-9032 databaseCode: M7P dateStart: 19880101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1349-7006 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0036494 issn: 1347-9032 databaseCode: 7X7 dateStart: 19880101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1349-7006 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0036494 issn: 1347-9032 databaseCode: BENPR dateStart: 19880101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1349-7006 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0036494 issn: 1347-9032 databaseCode: PIMPY dateStart: 19880101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVWIB databaseName: Wiley Online Library Free Content customDbUrl: eissn: 1349-7006 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0036494 issn: 1347-9032 databaseCode: WIN dateStart: 20030101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell – providerCode: PRVWIB databaseName: Wiley Online Library Open Access customDbUrl: eissn: 1349-7006 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0036494 issn: 1347-9032 databaseCode: 24P dateStart: 20030101 isFulltext: true titleUrlDefault: https://authorservices.wiley.com/open-science/open-access/browse-journals.html providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwELZoixAX_isWympAHJZDROI4m5gLaqutWomuovK3nCI7tmlESZbuFmlvPAKPw_PwJMx4k22LgAuHRIkzip3MeOwZj-dj7ClqvEwlUgWZ5TYQKjKBjrQNqExzaVzmo93fvUrH42wykXnrcJu1YZWdTvSK2jQl-cif41CSigSP4cvpl4BQo2h1tYXQWGMblCWB-9C9vNPE8VDIJaitSAMZxrzNLESRPAQohrYEIb1fHI_OJ5m_h0henLr6sWfv5v-2-ha70c46YXspJrfZFVvfYdcO23X1u-zHTqXIaQAesg8swcaixj6Bj2ilz49hicoDqB3tlC4EDPZHR-IZzBf4VfgK-FTVOB4ChYMo2uEO5OAFZFulGwpUfAEEEuI3UUDjgNYLwND0E_SiI1v8_Pa9A-WdA1UAFf0XIqZoWTDNZ1XVgEWU-IKc_PfY273Rm939oMV0CEqBlmAQu9ggO0KFpndstBOxLY1MEi2cEpZyD0VlqXVknOGax1rG1qTD0AiXGi21izfZet3U9j6DMOU8MhZNMFUKWwrtpNShk8PEoBkZRT026DhblG3Cc8LdOCk6wweFoPBC0GNPVqTTZZaPPxFtdTwu2o4-K84Z3GOPV4-xi9KvUbVtzogGNaUgSKgeSy-J1aoySvJ9-UldHftk35RtKM6w8oEXwL83r9jdfu0vHvy7nQ_ZdU4-Ax9yvMXW56dn9hG7Wn6dV7PTPlvjIsdzOkn9OeuzjZ3ROD_qe29F33cwLMsPDvMPePf-YPwLSgkyuA |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3NbtNAEB6VFAEX_hGBAgMCKRwsYu8m9iIhVEqrRE2iCAoqJ-P1rqlFsUOSUuXGI_AknHkenoQZ_6QtAm49cLC0ske7q_W3Mzu7s_MBPCSNF0QdFTmB9awjI9c42tXW4XfaUyYJimj3twN_NAp2d9V4Bb7Xd2E4rLLWiYWiNnnMe-RPyJT4skNP9_nks8OsUXy6WlNolLDYtotDctlmz_ov6f8-8rytzZ2NnlOxCjixJF_EEYkwQvrtiJw_YXQihY2N6nS0TCJpOfuNG8dauyYxnvaEVsIav9s2MvGNVjoRVO8ZWJUM9gasjvvD8bta94uuVCWNrvQd1RZelcuIY4eYwoy8F-aWP24Bj5a1vwdlHl8sF9Zu69L_Nk6X4WK1rsb1ciJcgRWbXYVzwypy4Br8eJFGvC2CBSkhWibGJZu0jx-m-eF8D0veIST9bydckNjqbb6Sj3G-oFGkKvBjmpHFRw54ifgOP_IWNhIwU51zKOZTZBqU4poI5gnyiQgaXmCjXtRii59fv9W0w3PkBjDl_8DCHA-MJv8UpRnSK07twccY1-HNqYzbDWhkeWZvArZ9z3ONJScziqWNpU6U0u1EdTuGHGXXbUKrRlIYVyndmVlkP6xdOwJdWICuCQ-WopMyj8mfhNZqTIWVKpuFR4Bqwv3lZ1JCPDRRZvMDliFbIJn0qgn-CRgvG-M05ie_ZOlekc6c8ymJgBpvFYD_e_fCjfXXReHWv_t5D873doaDcNAfbd-GCx7vkBQB1mvQmE8P7B04G3-Zp7Pp3Wr6Irw_7ZnwC9x1i4M |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLZGh6a9cEcUBhwQSOUhWmO7TY2E0NhWrdpWVVym8RTi2N4iRlLajKlv_AR-DuLn8Es4J5duQ8DbHniIFCVHseV8Phf7-HyMPUGN14s6KvJ6lltPRr7xtK-tR880V8b1imz3vZ1gOOzt76vRAvtRn4WhtMpaJxaK2mQxrZGvoikJZAev7qqr0iJGG_2X488eMUjRTmtNp1FCZNvOTjB8m74YbOC_fsp5f_Pt-pZXMQx4scS4xBNOGCGDdoSBoDDaSWFjozodLV0kLVXC8eNYa984wzUXWglrgm7bSBcYrbQT-N1LbBFdcskbbHE02B29r-2A6EpVUurKwFNtwau6RpRHRHRmGMkQz_xZa3jq4v6eoHnWcS4sX__q_zxm19iVyt-GtXKCXGcLNr3BlnarjIKb7PurJKLlEijICsESYS7aqiM4mGQn-SGUfESAdsGO6UZCa2vztXwG-QxHFD8BH5MUPQGgRJiIzvYDLW0DAjbRGaVoPgeiRymOj0DmgHZKwJDjDXpWi81-fv1W0xHnQA1AQv-EhClPGEz2KUpSwEdU8oO2N26xdxcybrdZI81Se4dBO-DcNxaDzyiWNpbaKaXbTnU7BgNo32-yVo2qMK5KvRPjyFFYh3wIwLAAYJM9nouOy_omfxJaqfEVVipuGp6Cq8kezV-jcqKhiVKbHZMM2ghJZFhNFpyD9LwxKm9-_k2aHBZlzqnOkuhh460C_H_vXri-9qa4ufvvfj5kSwj_cGcw3L7HljktnBR51yuskU-O7X12Of6SJ9PJg2omA_tw0RPhF9KYlEM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Biasing+human+epidermal+growth+factor+receptor+4+%28HER4%29+tyrosine+kinase+signaling+with+antibodies%3A+Induction+of+cell+death+by+antibody%E2%80%90dependent+HER4+intracellular+domain+trafficking&rft.jtitle=Cancer+science&rft.au=Lanotte%2C+Romain&rft.au=Garambois%2C+V%C3%A9ronique&rft.au=Gaborit%2C+Nad%C3%A8ge&rft.au=Larbouret%2C+Christel&rft.date=2020-07-01&rft.pub=John+Wiley+%26+Sons%2C+Inc&rft.issn=1347-9032&rft.eissn=1349-7006&rft.volume=111&rft.issue=7&rft.spage=2508&rft.epage=2525&rft_id=info:doi/10.1111%2Fcas.14458&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-9032&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-9032&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-9032&client=summon |